Danish Renewable Energy Stock News

Demant (CPSE:DEMANT) has drawn investor attention after CEO Søren Nielsen warned that upcoming EU AI rules could create overlapping medical device regulations, potentially affecting approval timelines and competitiveness for European hearing healthcare companies. See our latest analysis for Demant. That warning comes as Demant’s share price has moved sharply higher in the short term, with a 1 month share price return of 20.47% and 3 month share price return of 38.33%. This contrasts with a 1...

FLSmidth (CPSE:FLS) stock has been drawing attention after a mixed pattern of returns, with a gain of 13% over the past week, 3% over the past month, but a 6% decline over the past 3 months. See our latest analysis for FLSmidth. With the share price at DKK516.0, FLSmidth has produced a strong 1 year total shareholder return of 45.17%, while the 90 day share price return is down 6.35%, suggesting recent momentum has cooled after a solid longer term run. If this kind of move has you thinking...

Last week's profit announcement from Hove A/S ( CPH:HOVE ) was underwhelming for investors, despite headline numbers...

Københavns Lufthavne (CPSE:KBHL) is back in focus after reporting first quarter 2026 results alongside reaffirmed full year guidance, tying stronger passenger traffic to higher revenue, earnings and a projected 7% revenue increase for 2026. See our latest analysis for Københavns Lufthavne. Against this backdrop, the stock’s 1 day share price return of 1.37% sits within a weaker recent patch. The 90 day share price return is down 8.39% and the 1 year total shareholder return is down 10.88%,...

Readers hoping to buy TORM plc ( CPH:TRMD A ) for its dividend will need to make their move shortly, as the stock is...

It's been a good week for TCM Group A/S ( CPH:TCM ) shareholders, because the company has just released its latest...

H. Lundbeck A/S' ( CPH:HLUN B ) recent earnings report didn't offer any surprises, with the shares unchanged over the...

Bavarian Nordic (CPSE:BAVA) received a major contract extension from the US government’s BARDA for its JYNNEOS smallpox vaccine. The extension secures remaining JYNNEOS doses and includes an additional US$97 million commitment for further vaccine supply. The agreement supports a shift to a freeze dried formulation designed for longer shelf life and stockpile use. The company has updated its 2026 revenue and business guidance following the new BARDA commitments. For investors looking at...

Djurslands Bank Q1 2026 Earnings Snapshot Djurslands Bank (CPSE:DJUR) has reported Q1 2026 revenue of DKK 172.1 million and net income of DKK 54.4 million, setting the tone for a new financial year after a period where trailing twelve month revenue stood at DKK 701.3 million and net income at DKK 247.8 million. The bank has seen quarterly revenue move between DKK 157.1 million and DKK 198.1 million over the past year, while net income has ranged from DKK 45.4 million to DKK 83.6 million. This...

Aktieselskabet Schouw (CPSE:SCHO) has called a special meeting to review the offering circular and indicative price range for the planned IPO of its fish feed subsidiary, BioMar Group A/S, on Nasdaq Copenhagen. See our latest analysis for Aktieselskabet Schouw. The special meeting comes after a solid run for the stock, with a 1 month share price return of 5.24% and a 1 year total shareholder return of 20.43%. This points to improving momentum despite a modest 3 month share price decline of...

Investors may be wondering whether Vestas Wind Systems, at a recent price of DKK194.60, still offers value or if most of the opportunity is already priced in. The stock has returned 1.9% over the last 7 days, 1.6% over the last 30 days, 8.9% year to date, and 92.8% over the past year. Returns over the past 3 and 5 years show declines of 1.8% and 17.5% respectively. Recent headlines around Vestas Wind Systems have focused on the company as a key listed player in the global wind sector. This...

We wouldn't blame TORM plc ( CPH:TRMD A ) shareholders if they were a little worried about the fact that Jacob...

Rockwool (CPSE:ROCK B) has been drawing attention after a mixed run in its stock performance, with the share price up over the past month but down over the past 3 months and year. See our latest analysis for Rockwool. At a share price of DKK194.8, Rockwool’s recent 1 month share price return of 2.47% contrasts with a 1 year total shareholder return that declined 34.22%. This suggests recent momentum is improving after a weaker period. If Rockwool’s recent moves have you thinking about where...

TCM Group (CPSE:TCM) opened 2026 with Q1 revenue of DKK362.4 million and basic EPS of DKK1.45, setting the tone for how investors will read the latest numbers against the stock’s current price of DKK71.8. The company has seen quarterly revenue move from DKK308.1 million in Q1 2025 to DKK362.4 million in Q1 2026, while basic EPS shifted from DKK1.16 to DKK1.45 over the same period. Trailing twelve month EPS stands at DKK7.83 on revenue of DKK1,333.5 million, which puts the focus squarely on...

Last week, you might have seen that Matas A/S ( CPH:MATAS ) released its annual result to the market. The early...

Scandinavian Tobacco Group (CPSE:STG) has opened Q1 2026 with a recent quarterly run rate of DKK2,343.3 million in revenue and basic EPS of DKK2.1, set against a trailing 12 month revenue base that has moved from DKK9,202.1 million to DKK9,035.7 million while TTM EPS has shifted from DKK11.45 to DKK8.50. Over the same window, trailing net income excluding extra items has gone from DKK939.7 million to DKK669.4 million. The latest release therefore lands in a context where margins and earnings...

As the pan-European STOXX Europe 600 Index recently experienced a decline, driven by geopolitical tensions and inflationary concerns, investors are increasingly looking towards small-cap stocks for potential growth opportunities. In this environment, identifying companies with robust earnings growth and resilience to economic pressures can be key to enhancing an investment portfolio.

Novo Nordisk (CPSE:NOVO B) has transferred global rights to its clinical-stage allogeneic cell therapy for Parkinson's disease to Cellular Intelligence. The agreement includes an equity investment by Novo Nordisk, with the company also eligible for potential milestones and royalties. The Parkinson's program holds FDA Fast Track Designation, and Cellular Intelligence plans to apply AI tools to support clinical development and manufacturing. Novo Nordisk, traded as CPSE:NOVO B, is best known...

Matas (CPSE:MATAS) has wrapped up FY 2026 with Q4 revenue of DKK 1.98b and a reported loss of DKK 31m, while Basic EPS for the quarter came in at a loss of DKK 0.83. Over the past six reported quarters, revenue has ranged from DKK 1.88b to DKK 2.78b, with Basic EPS moving between a loss of DKK 0.08 and a profit of DKK 7.52 on a trailing twelve month basis, which currently stands at DKK 6.44. With trailing net margin at 2.8% versus 3.4% a year earlier, this set of results places profitability...

Q1 2026 results snapshot UIE (CPSE:UIE) has kicked off Q1 2026 with revenue of US$162.1 million and a reported loss per share of US$0.87, as net income excluding extra items came in at a loss of US$26.6 million. The company has seen revenue move from US$116.7 million in Q1 2025 to US$162.1 million in Q1 2026. Trailing twelve month EPS across the last reported periods ranged from US$2.37 to US$4.48 before settling at US$2.71 in Q1 2026, which puts the spotlight firmly on how sustainable its...

ISS (CPSE:ISS) has upgraded its 2026 outlook, flagging organic growth above 6% and an operating margin around 5.25%. The company has also expanded its share buyback programme to DKK 3.1 billion. See our latest analysis for ISS. The upgraded outlook, settlement with Deutsche Telekom and larger buyback programme have coincided with firm share price momentum, with a 30 day share price return of 12.36% and a 1 year total shareholder return of 64.03% suggesting improving sentiment over both...

Shareholders appeared unconcerned with Coloplast A/S' ( CPH:COLO B ) lackluster earnings report last week. Our analysis...

Rockwool (CPSE:ROCK B) has opened 2026 with Q1 revenue of €907 million and basic EPS of €0.40, setting the tone for investors assessing how the business is trading after a volatile 2025. Over recent quarters, revenue has held in a tight band between €907 million and €988 million, while quarterly EPS has moved between a profit of €0.60 and a loss of €1.79, capturing the swings that also pulled trailing 12 month EPS down to €0.02 on revenue of €3.9 billion. With a trailing net profit margin of...

Recent share performance and business context Novo Nordisk (CPSE:NOVO B) has drawn attention after recent price moves, with the stock up about 10.4% over the past month but down roughly 7.6% over the past 3 months. For context, the company reports annual revenue of DKK 327,800.0m and net income of DKK 121,957.0m, primarily from its Diabetes and Obesity Care segment, which accounts for DKK 307,350.0m of revenue. See our latest analysis for Novo Nordisk. At a share price of DKK287.5, Novo...